GM6
Amyotrophic Lateral Sclerosis (ALS)
Key Facts
About Genervon Biopharmaceuticals
Genervon Biopharmaceuticals is a private, clinical-stage company pioneering a master regulatory, multi-target approach to treating neurodegenerative diseases with its lead candidate, GM6. This peptide analog is designed to modulate multiple defective pathways common across disorders like ALS, Parkinson's, Alzheimer's, and MS, and has demonstrated safety and biomarker modulation in Phase 2A trials for ALS. Founded in 2001, the company holds extensive worldwide patents and is actively seeking partnerships to advance GM6 into late-stage clinical trials and ultimately to market.
View full company profileAbout Genervon Biopharmaceuticals
Genervon Biopharmaceuticals is a private, clinical-stage company pioneering a master regulatory, multi-target approach to treating neurodegenerative diseases with its lead candidate, GM6. This peptide analog is designed to modulate multiple defective pathways common across disorders like ALS, Parkinson's, Alzheimer's, and MS, and has demonstrated safety and biomarker modulation in Phase 2A trials for ALS. Founded in 2001, the company holds extensive worldwide patents and is actively seeking partnerships to advance GM6 into late-stage clinical trials and ultimately to market.
View full company profileAbout Genervon Biopharmaceuticals
Genervon Biopharmaceuticals is a private, clinical-stage company pioneering a master regulatory, multi-target approach to treating neurodegenerative diseases with its lead candidate, GM6. This peptide analog is designed to modulate multiple defective pathways common across disorders like ALS, Parkinson's, Alzheimer's, and MS, and has demonstrated safety and biomarker modulation in Phase 2A trials for ALS. Founded in 2001, the company holds extensive worldwide patents and is actively seeking partnerships to advance GM6 into late-stage clinical trials and ultimately to market.
View full company profileAbout Genervon Biopharmaceuticals
Genervon Biopharmaceuticals is a private, clinical-stage company pioneering a master regulatory, multi-target approach to treating neurodegenerative diseases with its lead candidate, GM6. This peptide analog is designed to modulate multiple defective pathways common across disorders like ALS, Parkinson's, Alzheimer's, and MS, and has demonstrated safety and biomarker modulation in Phase 2A trials for ALS. Founded in 2001, the company holds extensive worldwide patents and is actively seeking partnerships to advance GM6 into late-stage clinical trials and ultimately to market.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Phase 2/3 (Platform Trial) |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| Undisclosed Program | Zhimeng Biopharma | Clinical |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |
| NG CELL | NeuroGenesis Bio | Phase 2 |